The Art to Manage diabetic Foot Infection Focus : on Ertapenem (INVANZ®)

The Art to Manage diabetic Foot Infection
Focus : on Ertapenem (INVANZ®)

Diabetes is a serious chronic disease. In 2003 the global prevalence of diabetes was estimated at 194 million. This figure is predicted to reach 333 million by 2025 as a consequence of longer life expectancy, sedentary lifestyle and changing dietary patterns. This rise is to bring a proportional increase in the people with diabetes complications, including problems of the foot.
Diabetes mellitus is a disorder that primarily affects the microvascular circulation. In the extremities, microvascular disease due to "sugar-coated capillaries" limits the blood supply to the superficial and deep structures. Pressure due to ill-fitting shoes or trauma further compromises the local blood supply at the microvascular level, predisposing the patient to infection. The infection may involve the skin, soft tissues, bone, or all of these tissues. Diabetes also accelerates macrovascular disease, which is evident clinically as accelerating atherosclerosis and/or peripheral vascular disease.

The Cinula® is More Than Rationale Therapy in Diabetic Polyneuropathy

INTRODUCTION The Cinula® is a novel FDC of cunnulin PF 250mg, ALA 300mg Vit B12 100mcq, and Chromium (Cr), which has multiple therapeutic values for patients with obesity, prediabetes, the MetS, and T2DM. It can be used pathogenetically for patients with diabetic polineuropathy and oxidative stress (smoker etc). The link between increased body fat and insulin resistance has been generally recognized and accepted. It has become apparent that insulin resistance is actually associated with the increased in body fatness. The body composition of regional adipose depot-total body fat, deep subcutaneous fat, visceral fat– contributes most frequently to insulin resistance, and then prediabetes and the metabolic syndrome (the MetS) may pursue. The cinula®, the novel FDC cinnulin PF, ALA, and Vit B12, has biologic effects on body composition and prediabetes (Zeigenfuss et al 2006, 2007). The MetS is a “good example” of lifestyle related preclinical disease, and is an insulin resistant state associated with increased cardiovascular disease (CVD) risk. The MetS is usually been flanked by cardiometabolic risk factors, including various combinations of abdominal obesity, glucose intolerance, atherogenic dyslipidemia, hypertension prediabetes, and associated with a high risk of developing T2DM. The cinnamon extract has been demonstrated to improve the plasma glucose, A1C, and serum lipid of patients with T2DM (Khan et al 2003, Mang et al 2006, Zeigenfuss et al 2007). Antioxidant effects of a cinnamon extract in overweight or obese people with impaired fasting glucose have been studied by Roussel et al (2006). Alpha-lipoic acid (ALA), built in the cinula®, has antioxidant effects and has been demonstrated to be successful in the treatment of diabetic polyneuropathy, diabetic patients with insulin resistance, oxidative stress, hypertension, dyslipidemia and cardiovascular disease (Zeigler et al 2003, Midaoui et al 2002, Ametov et al 2003, Wollin et al 2003, Sola et al 2005, Young et al 2006). Vitamin B12, one component of the cinula®, has important roles in the treatment of diabetic neuropathy and also shows a pivotal role in the cognitive function. Chromium (Cr) content exists in the cinnamon, and it has been widely reported to play a role in the control of blood glucose of patients with diabetes mellitus which are due to its effects to improve insulin receptor and post receptor function.